Multiple Myeloma
7 protocols meet the specified criteria.
-
BMTCTN1704
Composite Health Assessment Model for Older Adults: Applying Pre-transplant Comorbidity, Geriatric Assessment, and Biomarkers to Predict Non-Relapse Mortality after Allogeneic Transplantation (CHARM) -
EA9171
Phase II Study of Adding the Anti-PD-1 Pembrolizumab to Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease -
EAA173
Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma -
PRE0905
Randomized Trial of Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia -
S1803
Phase III Study of Daratumumab/rHuPH20 (NSC-810304) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study) -
SIMPRO
SIMPRO Research Center: Integration and Implementation of PROs for Symptom Management in Oncology Practice. -
STRO-001-BCM1
A Phase I Open-Label, Safety, Pharmacokinetic, and Preliminary Efficacy Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients with Advanced B-Cell Malignancies